Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal

Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. The mechanisms for resistance remain unclear. In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book. It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal Presents timely contents based on current research, critical analyses, in-depth literature reviews, and up-to-date clinical reports of the resistance to anti-CD20 antibodies, aiming to produce solutions to current problems in the field Discusses discoveries of anti-CD20 antibodies in cancer treatment, the possible resistant mechanisms and their reversals, as well as the exciting therapeutic opportunities provided by the combination of anti-CD20 antibodies and chemotherapy Encompasses several diagrams and tables to help readers to get a clearer picture of the research findings and how they compare with other scientific data